<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990130</url>
  </required_header>
  <id_info>
    <org_study_id>00935</org_study_id>
    <nct_id>NCT02990130</nct_id>
  </id_info>
  <brief_title>Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Biochemical and Physiologic Factors That Affect Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garcia, Jose M., MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Garcia, Jose M., MD, PhD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal aims to characterize biochemical and physiologic factors that contribute to
      changes in patient fitness and body composition during hematopoietic stem cell
      transplantation (HCT) for hematologic malignancies. The study group will consist of 60
      patients with hematologic malignancies treated with HCT. Measurements of patient fitness,
      body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days
      (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA,
      additional visits (not exceeding 6 total) may be requested periodically for up to 2 years
      after HCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal aims to characterize biochemical and physiologic factors that contribute to
      changes in patient fitness and body composition during hematopoietic stem cell
      transplantation (HCT) for hematologic malignancies. The investigators hypothesize that: 1)
      HCT for hematologic malignancies is associated with a change in biochemical and physiologic
      factors that reflect patient fitness and 2) Baseline (pre-HCT) and post-HCT changes of
      biochemical and physiologic factors that reflect patient fitness are associated with
      HCT-related clinical outcomes.This is a pilot study involving patients enrolled in the
      Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy.
      No vulnerable population will be included. The study group will consist of 60 patients with
      hematologic malignancies treated with HCT.

      Measurements of patient fitness, body composition, and inflammatory milieu will be performed
      at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to
      receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested
      periodically for up to 2 years after HCT. Data collection may include:

        1. Blood tests other than those performed as clinical standard of care may include:
           anabolic and catabolic factors such as IGF-1, GH, IGFBP-3, free and weakly bound
           testosterone, IL-6, CRP, TNF-alpha, and pre-albumin.

        2. Measurements of fitness other than those obtained as clinical standard of care may
           include: resting energy expenditure (REE) assessed by indirect calorimetry; body
           composition measured by bio-impedance (BIA) and dual-energy x-ray absorptiometry (DEXA)
           scan; handgrip strength; stair climbing power; 6-minute walk test; muscle strength;
           maximal oxygen consumption (VO2 max); and previously validated questionnaires to assess
           patient quality of life (QOL) and functional status.

        3. Additional data that may be collected for this protocol will include clinical and
           laboratory data acquired per standard of clinical care as pertains to subjects'
           co-morbidities, hematologic disease and treatment history, and clinical course including
           nutritional status, use of nutrition support, and estimated nutritional requirements per
           routine dietitian assessments. A Food Frequency Questionnaire will be administered by a
           dietitian in addition to the routine clinical assessments.

      The primary endpoint of this study is the change over time of patient fitness as assessed by
      the 6 minute walk test through HCT. Secondary endpoints will include other markers of
      anabolism and catabolism, and data collected as mentioned above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6-Minute Walk Test change</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>maximum distance walked in 6 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anabolic marker changes</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>IGF-1, GH, IGFBP-3, free and weakly bound testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker changes</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>IL-6, CRP, TNF-alpha, and pre-albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>handgrip strength; 1-RM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting energy expenditure changes</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition changes</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>bio-impedance and dual-energy x-ray absorptiometry (all in kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical function changes</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>stair climbing power</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximal oxygen consumption changes</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>VO2 max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life change score</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>ASAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life change score</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>FACIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life change score</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>Karnofsky</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life change score</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
    <description>ECOG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Frequency Questionnaire</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of nutrition support</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated nutritional requirements</measure>
    <time_frame>from baseline to 30 days (+/- 10 days) after HCT</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study group will consist of 60 patients with hematologic malignancies treated with HCT
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed hematologic malignancy.

          -  Undergoing evaluation at the BMTU at the Puget Sound VA.

          -  Planning or receiving an autologous or allogeneic HCT

        Exclusion Criteria:

        â€¢ Patients who for any reason elect not to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose M Garcia, MD, PhD</last_name>
    <phone>206-764-2984</phone>
    <email>jose.garcia@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsey J Anderson, PhD</last_name>
    <phone>206-277-6719</phone>
    <email>lindsey.anderson5@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Garcia, MD, PhD</last_name>
      <phone>206-764-2984</phone>
      <phone_ext>72984</phone_ext>
      <email>jose.garcia@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

